Vasomune Therapeutics and AnGes, Inc. enter into a Multi-Million Dollar Global Co-Development Agreement to Advance an Innovative Platform Targeting Vascular Leakage
Tokyo, Japan and Toronto, Ontario, July 31, 2018 (GLOBE NEWSWIRE) — Vasomune Therapeutics (“Vasomune”), a Toronto-based spin-out from Sunnybrook Research Institute and MaRS Innovation, and AnGes, Inc.
A New Flu Drug Works Astoundingly Well—By Not Targeting the Flu at All. Continue reading at Motherboard Vice.
Lifetime: New approach to fighting influenza Advertise on CTVNews.ca